Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05074953
Other study ID # POINTED
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date December 31, 2023

Study information

Verified date February 2024
Source Technische Universität Dresden
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The SARS-CoV-2 infection was in 2020 responsible for new disease related chronic conditions which have been referred to as Post-COVID. To date it is still unknown how common this condition is and which symptoms are related to it. The aim of the study is to monitor the onset of these conditions in a large observational study consisting of German health insurance data.


Description:

SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand the prevalence and variety of Post-COVID a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID. The basic question concerns the burden of the Post-COVID condition. The study investigate which symptoms are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in the subgroup of children and adolescents and those who have been hospitalized due to the virus infection.


Recruitment information / eligibility

Status Completed
Enrollment 157134
Est. completion date December 31, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - At least one outpatient or inpatient diagnosis of COVID-19 with laboratory detection of the virus (ICD-10: U07.1!) - Continuously insured with the respective health insurance between 2019-01-01/birth and 2020-12-31/death Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exposed to a SARS-CoV-2 infection
The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.

Locations

Country Name City State
Germany Center for Evidence-Based Healthcare Dresden Saxony

Sponsors (7)

Lead Sponsor Collaborator
Technische Universität Dresden AOK Bayern, AOK PLUS, BARMER Institut für Gesundheitssystemforschung (bifg), DAK Gesundheit, InGef - Institut für angewandte Gesundheitsforschung Berlin GmbH, Techniker Krankenkasse

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, Wende D, Vivirito A, Toepfner N, Ehm F, Seifert M, Nagel O, Konig C, Jucknewitz R, Armann JP, Berner R, Treskova-Schwarzbach M, Hertle D, Scholz S, Stern S, Ballesteros P, Bassler S, Bertele B, — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of abdominal pain Incidence of a diagnosis of abdominal pain recorded in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of acute pain Incidence of a diagnosis of acute pain recorded in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of adjustment disorder Incidence of a diagnosis of adjustment disorder recorded in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of anuria/oliguria Incidence of a diagnosis of anuria/oliguria in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of anxiety disorder Incidence of a diagnosis of anxiety disorder in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of arthritides Incidence of a diagnosis of arthritides in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of ascites Incidence of a diagnosis of ascites in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of behavioral symptoms Incidence of a diagnosis of behavioral symptoms in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of cachexia Incidence of a diagnosis of cachexia in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of carditis due to viruses Incidence of a diagnosis of carditis due to viruses in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of changes in bowel habits Incidence of a diagnosis of changes in bowel habits due to viruses in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of chronic fatigue syndrome Incidence of a diagnosis of chronic fatigue syndrome in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of cognitive function impairment Incidence of a diagnosis of cognitive function impairment in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of concentration impairment/concentration deficit Incidence of a diagnosis of concentration impairment/concentration deficit in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of cough Incidence of a diagnosis of cough in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of COVID toe Incidence of a diagnosis of COVID toe in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of depression Incidence of a diagnosis of depression in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of developmental delay Incidence of a diagnosis of developmental delay in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of disorientation Incidence of a diagnosis of disorientation in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of dysgeusia Incidence of a diagnosis of dysgeusia in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of dyslexia Incidence of a diagnosis of dyslexia in in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of dysmenorrhea Incidence of a diagnosis of dysmenorrhea in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of dysphagia Incidence of a diagnosis of dysphagia in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of dyspnea Incidence of a diagnosis of dyspnea in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of dysuria Incidence of a diagnosis of dysuria in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of emotional and behavioral disorder Incidence of a diagnosis of emotional and behavioral disorder in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of epistaxis Incidence of a diagnosis of epistaxis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of eye pain Incidence of a diagnosis of eye pain in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of facial nerve paralysis Incidence of a diagnosis of facial nerve paralysis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of fever Incidence of a diagnosis of fever in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of flatulence Incidence of a diagnosis of flatulence in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of gangrene Incidence of a diagnosis of gangrene in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of general symptoms Incidence of a diagnosis of general symptoms in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of hair loss Incidence of a diagnosis of hair loss in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of headache Incidence of a diagnosis of headache in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of hearing loss/tinnitus Incidence of a diagnosis of hearing loss/tinnitus in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of heart failure Incidence of a diagnosis of heart failure in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of heart murmurs Incidence of a diagnosis of heart murmurs in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of heartburn Incidence of a diagnosis of heartburn in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of hemorrhage Incidence of a diagnosis of hemorrhage in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of hepatomegaly and splenomegaly Incidence of a diagnosis of hepatomegaly and splenomegaly in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of hoarseness Incidence of a diagnosis of hoarseness in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of hyperhidrosis Incidence of a diagnosis of hyperhidrosis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of hypotension Incidence of a diagnosis of hypotension in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of impaired balance Incidence of a diagnosis of impaired balance in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of joint pain Incidence of a diagnosis of joint pain in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of loss of appetite Incidence of a diagnosis of Loss of appetite in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of lymphadenopathy Incidence of a diagnosis of lymphadenopathy in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of Malaise/fatigue/exhaustion Incidence of a diagnosis of Malaise/fatigue/exhaustion in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of memory impairment Incidence of a diagnosis of memory impairment in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of meningismus Incidence of a diagnosis of meningismus in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of mood disorder Incidence of a diagnosis of mood disorder in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of movement disorders Incidence of a diagnosis of movement disorders in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of myalgia Incidence of a diagnosis of myalgia in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of myocardial infarction Incidence of a diagnosis of myocardial infarction in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of myocarditis Incidence of a diagnosis of myocarditis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of nausea Incidence of a diagnosis of nausea in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of neurasthenia Incidence of a diagnosis of neurasthenia in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of neurological manifestation of Post-COVID Incidence of a diagnosis of Neurological manifestation of Post-COVID in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of obsessive-compulsive disorder Incidence of a diagnosis of obsessive-compulsive disorder in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of oedema Incidence of a diagnosis of oedema in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of other cardiac arrhythmias Incidence of a diagnosis of other cardiac arrhythmias in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of other coordination disorders/ataxia Incidence of a diagnosis of other coordination disorders/ataxia in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of other symptoms of the urinary system Incidence of a diagnosis of other symptoms of the urinary system in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of pain, not elsewhere classified Incidence of a diagnosis of pain, not elsewhere classified in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of paresis Incidence of a diagnosis of paresis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of paresthesia of skin Incidence of a diagnosis of paresthesia of skin in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of pathological findings from male genital tract Incidence of a diagnosis of pathological findings from male genital tract in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of pathological lung findings Incidence of a diagnosis of pathological lung findings from male genital tract in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of pathological reflexes Incidence of a diagnosis of pathological reflexes in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of pericarditis Incidence of a diagnosis of pericarditis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of polyuria Incidence of a diagnosis of polyuria in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of Post-COVID Incidence of a diagnosis of Post-COVID in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of pulmonary embolism Incidence of a diagnosis of pulmonary embolism in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of rash Incidence of a diagnosis of rash in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of respiratory insufficiency Incidence of a diagnosis of respiratory insufficiency in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of seizures Incidence of a diagnosis of seizures in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of sensation and perception disorder Incidence of a diagnosis of sensation and perception disorder in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of shock Incidence of a diagnosis of shock in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of sinus vein thrombosis Incidence of a diagnosis of sinus vein thrombosis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of sleep disorders Incidence of a diagnosis of sleep disorders in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of somatization disorder Incidence of a diagnosis of somatization disorder in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of somnolence Incidence of a diagnosis of somnolence in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of sopor/coma Incidence of a diagnosis of sopor/coma in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of speech and language disorders Incidence of a diagnosis of speech and language disorders in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of stroke Incidence of a diagnosis of stroke in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of subcutaneous nodules Incidence of a diagnosis of subcutaneous nodules in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of syncope Incidence of a diagnosis of syncope in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of tetany Incidence of a diagnosis of tetany in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of throat/chest pain Incidence of a diagnosis of throat/chest pain in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of thrombosis Incidence of a diagnosis of thrombosis in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of urethral discharge Incidence of a diagnosis of urethral discharge in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of urinary retention Incidence of a diagnosis of urinary retention in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of vertigo Incidence of a diagnosis of vertigo in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of visual disturbances Incidence of a diagnosis of visual disturbances in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
Primary Incidence of weight gain/loss, eating disorders Incidence of a diagnosis of weight gain/loss, eating disorders in outpatient or inpatient setting At least 12 weeks after the infection by SARS-CoV-2
See also
  Status Clinical Trial Phase
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT04644484 - A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety Phase 3
Completed NCT00984945 - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults Phase 1
Completed NCT00734175 - Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine Phase 1
Completed NCT00516035 - Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults Phase 1
Active, not recruiting NCT05284097 - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Phase 2
Completed NCT03739112 - Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Phase 3
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT01991587 - Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults Phase 1/Phase 2
Completed NCT03294135 - The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine Phase 4
Active, not recruiting NCT02545517 - A Clinical Study to Evaluate Immune Responses to Rabies Vaccine in Adults Who Received Different Primary Rabies Vaccination Regimens Phase 3
Active, not recruiting NCT05619770 - Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects Phase 1
Not yet recruiting NCT01289301 - Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant Phase 4
Active, not recruiting NCT01055990 - Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients Phase 2
Completed NCT00980447 - Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults Phase 2
Completed NCT01842997 - Safety of H1N1 Influenza Vaccination in Pregnant Women Phase 4
Completed NCT00380237 - Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) Phase 1
Completed NCT00219453 - Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination Phase 1
Completed NCT02548078 - A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children Phase 2

External Links